Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
News Article updated on 10/01/2021
-
Four Things to Know About Open Enrollment 2022
-
Hybrid Format for Ryan White 2022
Next year’s Ryan White Conference will adopt an in-person/virtual format, while the Clinica
News Article updated on 10/15/2021 -
Rapid ART: An Essential Strategy for Ending the HIV Epidemic
What HIV care providers can do to create a rapid ART program to get HIV clients on treatment the same day as a diagnosis.Resource updated 09/19/2023
-
Four things to know about Open Enrollment 2022
To help you stay on top of the latest updates, the ACE TA Center has compiled this list of four “things to know” about helping consumers navigate this year’s Marketplace Open Enrollment.Blog updated 11/09/2021
-
Rapid ART Playbook Outlines Steps to Implementation
Guide on implementing rapid ART the administration of antiretroviral therapy (ART) as quickly as possible and ideally on the same day as an HIV diagnosis/clinic visit.Blog updated 03/03/2022
-
TAP-in EHE Webinar Series
Recordings of the TAP-in webinars on topics critical to the Ending the HIV Epidemic Initiative.Resource updated 05/23/2023
-
Needs Assessment Tool Series: Focus Groups
-
Use of Social Media and Mobile Technology as Essential Tools for EHE
Strategies to engage hard-to-reach youth and young adults through use of social media and related technologies.Resource updated 03/15/2023
-
Marketplace Subsidies and Unemployment Compensation
New Marketplace subsidies are available for people who received unemployment compensation in 2021.Blog updated 12/15/2021
-
ADR Town Hall
ADAP discussion session on the 2022 ADR submission process.Resource updated 08/16/2023
-
Ending the HIV Epidemic through Innovations in Rapid ART
Review of innovative Rapid ART strategies in diverse settings.Resource updated 03/15/2023
-
Medical Monitoring Project 2019-2020 Data on HIV Care Access and Health Outcomes
In the U.S., almost all people with HIV have some type of health insurance coverage (pub
News Article updated on 08/09/2021 -
HIV 101: Fundamentals of HIV Pathogenesis, Antiretroviral Therapy Initiation, & Primary Care for PWH
Session for clinicians new to the field of HIV or those looking for a review on the core principles of HIV management, including pathogenesis of HIV infection, mechanism of action of antiretroviral drugs, initiating antiretroviral therapy, and primary care for people with HIV.Resource (Conference Presentation) updated 09/14/2023
-
Integrated HIV Prevention and Care Plan: Planning Requirements
Outline of the planning requirements for RWHAP Parts A and B recipients and all DHAP-funded state and local health departments as described in the Integrated HIV Prevention and Care Plan Guidance, Including the SCSN, CY 2022-2026.Resource updated 08/03/2023
-
ADR In Focus: Partial Premiums
Full versus partial premiums for ADR client-level data reporting and reporting strategies.Resource updated 09/14/2023
-
New Investigational ART Drugs and Strategies
Review of investigational drugs in phase III trials (as of 2021: Islatravir, Lenacapravir, GSK 3640254/aka GSK “254) and how these investigational agents might be used in treatment in the future. Also, review of long-acting injectables.Resource (Conference Presentation) updated 09/14/2023
-
Managing Polypharmacy and Drug-Drug Interactions
Review of common mechanisms for drug interactions with contemporary ART; therapeutic classes of drugs with high interaction potential with ART; distinctions between oral vs intramuscular cabotegravir/rilpivirin interactions; and comparison of the clinical pharmacology and drug interaction potential of tenofovir alafenamide vs tenofovir disoproxilfumarate.Resource (Conference Presentation) updated 09/14/2023
-
Cases From the Clinic(ians): Antiretroviral Therapy Cases and Panel Discussion
Insights for clinicians on selecting antiretroviral therapy and/or managing patients who: are starting initial therapy; are Elite Controllers; have InSTI-associated weight gain; have persistent low-level viremia; have a discordant CD4+ count response to ART; have ‘Blips’; and/or are aging.Resource (Conference Presentation) updated 04/08/2024
-
Expanded Access to Subsidized Marketplace Insurance Plans
Did you know? Most people with very low incomes can now enroll in subsidized Marketplace coverage.Blog updated 04/14/2022